Volition’s first supply and licensing contract for Nu.Q screening test in Asia

Published on 21 December 2021

Volition is a multinational epigenetics company that applies its Nucleosomics platform through subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis, such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on diagnostics and monitoring in humans but also has a subsidiary focused on animals.

In this video, we talk to Dr Tom Butera, chief executive officer of Volition Veterinary, about the company’s first supply and licensing contract for its Nu.Q vet cancer screening test. The contract is with SAGE Healthcare, a leading distributor of premium veterinary products and services in Asia.

Share this with friends and colleagues